More specifically, the NCCN guidelines recommend that FLT3 testing be performed at diagnosis in all patients with AML, in parallel with cytogenetic testing, to identify those who may benefit from targeted treatment options [5]. The gene discussed is FLT3; the disease is acute myeloid leukemia.